

# ***Antimicrobial Drugs***

## ***short review***

***Presented by***

***M.R. Salehi ,***

***MD***

***&***

***Infectious diseases specialist***

***Tehran university of medical sciences***

# **Approach to the Antibiotic therapy**

❖ **Host factors**

❖ **Site of infection**

❖ **Local resistance profiles of suspected or known  
pathogens**

❖ **Regularly monitoring of the patients and collection  
of laboratory data**

# Empirical and directed therapy

- ❖ **Empirical therapy** is considered when the causative agent has yet to be determined and therapeutic decisions are based on the severity of illness and the clinician's assessment of likely pathogens.
- ❖ **Directed therapy** is predicated on identification of the pathogen.

**Directed therapy** generally allows the  
use of **more targeted** and  
**narrower- spectrum**  
antibacterial agents than does  
**empirical therapy.**

When **empirical treatment** is clinically appropriate, care should be taken to obtain **clinical specimens** for microbiologic analysis **before the initiation of the therapy** and to **de-escalate therapy** as new information is obtained about the patients clinical conditions and the casual pathogens.

Multiple essential components of **bacterial cell structures** and **metabolism** have been the targets of antibacterial agents used in clinical medicine, and the interaction of an agent with its target results in either **inhibition of bacterial growth and replication**(*bacteriostatic effect*) or **bacterial killing ( *bactericidal effect*).**

**EXAMPLES:**  
Chloramphenicol  
Erythromycin  
Clindamycin  
Sulfonamides  
Trimethoprim  
Tetracyclines



**EXAMPLES:**  
Aminoglycosides  
Beta-lactams  
Vancomycin  
Quinolones  
Rifampin  
Metronidazole



**Treatment with bacteriostatic agents**  
is effective when the patient host  
**defenses are sufficient** to contribute to  
eradication of the infecting pathogen.  
In patient with **impaired host defenses**  
**(neutropenia)** or **infections in special**  
**body sites(meningitis & endocarditis)**  
**bactericidal agents** are generally  
preferred.




This understanding that **shorter**  
**antibiotic courses** are less likely than  
longer ones to promote the  
emergence of resistance is true.

Shorter Is Better With Antibiotics:  
Lessons & Resources

# ***Beta-lactam antibiotics:***

- \* **Penicillins**
- \* **Cephalosporins**
- \* **Carbapenems**
- \* **Monobactams**
- \* **Beta-lactamase inhibitors**



All Beta-lactams exert a **bactericidal effect**  
by inhibiting  
**bacterial cell-wall synthesis.**

They are **time dependent** killing agents.

# Penicillins

is the first beta-lactam that was discovered in **1928** by **Alexander Fleming**.



❖ **Penicillins can be divided into five classes**  
on the basis of antibacterial activity :

***Natural penicillins***—penicillin G, penicillin V

***Penicillinase-resistant penicillins***—  
methicillin, nafcillin,

***Aminopenicillins***—ampicillin and  
amoxicillin

***Carboxypenicillins***—carbenicillin , ticarcillin

***Acyl ureidopenicillins***—piperacillin.

# Penicillin G

Highly active against **Gram positive cocci:**

***Streptococcus pyogen* , *bovis* , *viridance***

***Most anaerobes*** (with certain **exceptions,**  
such as **Bacteroides**)

***Treponema pallidum***

## ***Penicillin G***

remains the primary agent for  
treatment of infections due to  
**Streptococcus pyogenes or Group A  
streptococcus (GAS)**



## IV penicillin G

remains the treatment of choice  
for susceptible pneumococcal and  
meningococcal meningitis,  
streptococcal and enterococcal  
endocarditis, and neurosyphilis.

**Neisseria gonorrhoeae** strains frequently are *resistant* to penicillin, which is *no longer recommended* for treatment of gonorrhea.

**\*Penicillin G is the drug of choice for syphilis at all stages.**

## ***Puerperal infections***

due to anaerobic streptococci or group

**B streptococci**

**(Streptococcus agalactiae)**, as well as

genital clostridial infections, are

treated with **penicillin G.**

# **Penicillinase-Resistance penicillins(PRP)**

**Anti staphylococcal penicillins (nafcillin,  
oxacillin, cloxacillin and dicloxacillin,  
flucloxacillin)**

inhibit penicillinase-producing

**S. aureus and S.epidermidis**

The **penicillinase-resistant penicillins**  
are indicated **solely** for the treatment of  
infections caused by  
**methicillin-susceptible strains of**  
**staphylococci(MSSA),**  
for which they are the agents of choice.

## ***Ampicillin, Amoxicillin***

are able to penetrate the porin channel of

***Gram negative bacteria***

but **not stable to *beta-lactamases***.

Active against the **E. coli, Proteus,  
Salmonella, Shigella, and Haemophilus  
influenzae , Enterococi, Listeria**

***\*None***

**of the broad spectrum penicillins are  
effective against  
penicillinase-producing  
*staphylococci***

## ***Aminopenicillins***

are indicated for treatment of **upper and lower respiratory tract infections,** gastroenteritis, endocarditis, meningitis, and **UTI** caused by **susceptible organisms.**



***Amoxicillin***, because of  
its excellent bioavailability, is the preferred  
agent for  
oral administration in most situations;  
it is well tolerated even in  
***high doses*** up to ***4 g/day***.

***Amoxicillin*** is recommended as a  
***single 2-g oral dose*** for prophylaxis  
of ***bacterial endocarditis***  
for those with the **highest risk** of  
adverse outcome.

# ***beta-lactamase inhibitors***

***Clavulanate,***

***Sulbactam,***

***Tazobactam***

inhibitors which have little intrinsic anti  
bacterial activity but **inhibit** the activity of a  
number of **plasmid-mediated beta-lactamases**

## ***Amoxicillin-clavulanate***

has proved useful as therapy for  
***acute otitis media, sinusitis***  
or ***pneumonia***.

It is particularly useful to treat  
**polymicrobial infections** including  
***bite wounds***  
of human or animal origin.

# ***Cephalosporins***

***In clinical practice, grouped into **five**  
"generations" based upon their  
spectrum of activity against aerobic  
and facultative Gram negative bacilli.***

# First-Generation Cephalosporins

The first-generation cephalosporins available in IRAN are ***cefazolin, cephalotin, cefadroxil , cephalixin.***

They have been extensively used as alternatives to penicillin for ***staphylococcal (MSSA).***

**Most commonly,**

these include ***skin and soft tissue infections.***

## ***Cefazolin***

is still recommended in  
**penicillin-allergic patients for more  
serious staphylococcal infections,  
such as endocarditis**

## ***Cefazolin***

is recommended as the  
**prophylactic antibiotic** of  
choice for **foreign-body implantation**  
and for many  
**clean and clean contaminated**  
**surgical procedures** in which there is a  
**high risk of infection.**



The **oral** first-generation cephalosporins,  
***cephalexin***

have **very high oral bioavailability**.

These drugs provide appropriate  
***outpatient***

therapy for many

*Cephalexin* has  
**poor activity against pneumococci,  
H. influenzae, M. catarrhalis**  
and is not recommended for  
sinusitis, otitis media,  
or lower respiratory tract infections.

\*The drug is effective in  
*uncomplicated urinary tract infections*

# Third-generation cephalosporins

available in the Iran are

*cefixime, cefotaxime, ceftazidime,  
and ceftriaxone.*

(cefoperazone, cefpodoxime)

**Third-generation cephalosporins** are major drugs for the treatment of many important infections because of their high antibacterial **potency**, **wide spectrum of activity**, low **potential for toxicity**, and favorable pharmacokinetics (*enhanced drug concentrations in the CSF*).

They have been especially useful in  
infections resulting from  
***gram-negative bacilli***  
that are  
**resistant to**  
**other  $\beta$ -lactam antibiotics.**

***Ceftriaxone*** has the longest half-life and is usually administered **once or twice daily**.

***Ceftazidime*** is dosed **two or three times daily**.

***Cefotaxime*** has the shortest half-life, has varied from every **4 h to three times daily**.

**Treatment of meningitis** requires

*maximal doses* of these

cephalosporins, such as

***2 g every 12 hours for ceftriaxone,***

**and 2 g every 4 to 6 hours in adults for**

**cefotaxime.**

***Cefotaxime and ceftriaxone*** continue to be active against most bacteria producing **CAP**.

\*The oral third-generation cephalosporin ,***cefixime*** is approved for oral therapy of mild-to-moderate respiratory infections, such as ***otitis media, sinusitis***.



***Ceftriaxone 250 to 500 mg IM***

**is highly active against**

**N. Gonorrhoeae.**

**It is the drug of choice for  
all forms of gonococcal infection and is  
used in combination with a  
single oral dose of azithromycin or  
7 days of oral doxycycline.**

***Ceftriaxone and Cefixime***

are a recommended

***alternative therapy*** for ***typhoid fever***

and for severe infections caused by

***Shigella.***

# Fluoroquinolones

- nalidixic acid

ofloxacin

lomefloxacin,

Levofloxacin,

gatifloxacin,

ciprofloxacin

norfloxacin,

enoxacin,

trovafloxacin,

moxifloxacin

# Quinolones

Quinolones are most active against aerobic

*gram-negative bacilli*, particularly

Enterobacteriaceae and Haemophilus and against

gram-negative cocci, such as

Neisseria and Moraxella catarrhalis.

\*Relative to nalidixic acid, the fluoroquinolones also have additional activity against *P. aeruginosa*

Because of the *risk of selection* of resistance during fluoroquinolone treatment of *serious pseudomonal* infections, these agents are usually used *in combination* with an antipseudomonal Beta lactam.

***Ciprofloxacin*** and ***levofloxacin*** have  
the broadest spectrum of the activity  
against ***gram-negative bacteria***,  
including ***P.aeruginosa***

*\*Levofloxacin, moxifloxacin, and  
gemifloxacin*

have improved activity against

*S. pneumoniae* and have

been referred to

*respiratory quinolones.*

Ciprofloxacin, ofloxacin, levofloxacin,  
gatifloxacin, and moxifloxacin  
are active against  
***M. tuberculosis.***



# CLINICAL USES

## *Urinary Tract Infections*

Concentrations of many

quinolones in urine are *usually sufficient*.

*For uncomplicated UTI, usually in symptomatic young women with cystitis, most quinolones are likely to be highly effective when given for brief courses of 3 to 10 days, and have been found to be comparable to TMP-SMX and nitrofurantoin*

**Fluoroquinolones *concentrate in* *prostatic tissue*.**

**In one small comparative study of men with predominantly E. coli infections, norfloxacin given for 4 to 6 weeks was superior (92% eradication) to TMP-SMX (67% eradication) at 1-month follow-up.**

After the emergence of  
*quinolone resistance* among  
*N. gonorrhoeae*, the Centers for Disease  
Control and Prevention (**CDC**),  
updated its recommendations and  
**removed** fluoroquinolones from the  
treatment guidelines.

# Aminoglycosides

- Aminoglycosides are highly potent, broad-spectrum antibiotics
  - with **Gram-negative antibacterial** therapeutic coverage that **inhibit protein synthesis**
  - Their history begins in **1944 with streptomycin**

# Aminoglycosides

Although marked **regional and individual hospital differences** exist for in vitro susceptibility patterns, the majority of aerobic and facultative **gram-negative bacilli, including *Enterobacteriaceae*, *P. aeruginosa*, and *Acinetobacter* remain** susceptible to gentamicin, tobramycin, and amikacin.

Aminoglycosides are used successfully  
in the treatment of  
intracellular infections, such as  
**brucellosis, tuberculosis.**

## ***Clinical uses***

\*most commonly ***in combination*** with  
other antibacterial agents (synergism)  
***complicated urinary tract infections***  
***intra abdominal infections***

\*selected aminoglycosides clinically  
relevant activity against

**protozoa (paromomycin),**

**N. gonorrhoeae (spectinomycin)**

**Mycobacterial infections (amikacin)**



# Clindamycin

- is a **lincosamide** antibiotic and is ***bacteriostatic*** against some organisms and ***bactericidal*** against others.
- Chemical modification of lincomycin provided clindamycin with increased **antibacterial potency** and **absorption after oral administration**.

Treatment against  
**anaerobic and aerobic streptococci**

(except enterococci)

most staphylococci

Bacteroides.fragilis, clostridium  
perferigens, fusobacterium and  
Actinomyces, bacterial vaginosis

***Clindamycin*** is used for treatment of  
dental infections,  
lung abscess and  
skin soft tissue infections.

# Metronidazole

- is one of the mainstay drugs for the treatment of **anaerobic infections**.
- Despite extensive worldwide use, acquired **resistance to metronidazole among anaerobic bacteria is rare**.
- Metronidazole is **well absorbed** after oral administration and is virtually **100 percent** bioavailable

# Metronidazole

## Treatment of

- *anaerobic bacterial*
- *Amebiasis*
- *symptomatic and asymptomatic trichomoniasis;*
  - *intra-abdominal infections*  
*(as part of combination regimen)*

**\*treatment of**

***pseudomembranous colitis***

***\*bacterial vaginosis***

**\*as part of a multidrug regimen for**


**H. pylori eradication**

Some studies have demonstrated that elimination of metronidazole metabolites may be reduced among those with

*renal insufficiency*, but there are no specific recommendations for dose reduction in this patient population

# Disulfiram-like reactions

- There have been case reports suggesting a possible disulfiram-like reaction **when metronidazole is administered systemically or vaginally to patients drinking ethanol.**
- causes **flushing, tachycardia, palpitations, nausea, and vomiting**
- recommends ***avoiding alcohol ingestion during metronidazole therapy and for at least 48 hours afterwards***





# Tetracyclines

- *Chlortetracycline* was the first tetracycline discovered, *in 1948*.
- *Tigecycline* is the first of this new class of agents and exhibits *broad-spectrum antibacterial activity* similar to the tetracyclines.

# Tetracyclines

- *Doxycycline, Minocycline, Tetracycline and Tigecycline* inhibit protein synthesis and are *bacteriostatic*.
- They have wide clinical use: skin soft tissue infections (MRSA), Spirochetal infections ( Lyme dis, syphilis, leptospirosis and relapsing fever), atypical pneumonia, STI( C.trachomatis, LGV) & Brucellosis.

Doxycycline may **be an alternative for use in children** since it binds calcium to a lesser extent than tetracycline, which can cause tooth discoloration and bony growth retardation.

***Tigecycline*** has a broader spectrum of activity.

Tigecycline has activity against gram-positive pathogens including: Enterococcus (VRE), Listeria, Streptococcus, both methicillin-susceptible and -resistant *S. aureus*, and *S. epidermidis*. Its gram-negative activity includes: Acinetobacter, Citrobacter, Enterobacter, Escherichia coli, Klebsiella.

*Dose adjustment is not necessary for doxycycline or tigecycline* in patients with **renal dysfunction**, and thus, these are the preferred tetracyclines in this population

Tetracyclines can cause ***fetal toxicity*** when given to ***pregnant women*** and should generally not be used in ***pregnant*** women or children under the age of eight years.

# Antimicrobial stewardship

- *Increasing prevalence of MDR bacteria* with a substantial amount of inappropriate antimicrobial use, the need for rational antimicrobial prescribing has never been greater.
- The practice of promoting the **selection** of the *appropriate drug, dosage rout* and **duration** of antimicrobial therapy.

# Antimicrobial stewardship gold

- *Improve patient care* through appropriate antimicrobial use
- *Decrease the development of resistance* within patient and population
- *Reduce the incidence of adverse effects*
  - *Control costs*



Fever  
is not a sign  
of ceftriaxone  
deficiency

